The Global Coalition for Adaptive Research (GCAR) unites physicians, clinical researchers, advocacy and philanthropic organizations, biotech/pharma, health authorities, and other key stakeholders in healthcare to expedite the discovery and development of treatments for patients with rare and deadly diseases.
As Sponsor of innovative trials, including master protocols and adaptive platform trials, GCAR is dedicated to the advancement of science by modernizing clinical trials that support more efficient, less costly drug development. Adaptive platform trials can accelerate the time from discovery in the lab to implementation in the clinic resulting in better treatments and lives saved.
COALITION BY COLLABORATION
By developing and operationalizing innovative clinical trials with some of the world’s foremost clinical, translational, basic science investigators and trial experts — and as a 501(c)(3) non-profit — GCAR is uniquely positioned to foster the collaboration required to design and sponsor innovative trial designs.
In February 2015, more than 130 global collaborators — researchers, clinicians, biostatisticians, patient advocates, and others — came together for a series of meetings to brainstorm new ideas. A protocol draft for GBM AGILE was developed and, working with the FDA, was revised and refined to yield a remarkable result. The GBM AGILE structure would have broad eligibility to maximize learning and participation, and the design would allow promising therapies to be quickly developed and approved by the FDA. GBM AGILE would also foster development of precision medicines by understanding which patients benefit most from experimental therapies based on their biomarker profile.
In April 2017, the Global Coalition for Adaptive Research (GCAR), a 501(c)3 not for profit corporation, was founded by Brian Alexander, Sujuan Ba, Web Cavenee, Tim Cloughesy, John Frishkopf, and Faramarz Yousefzadeh to be the Sponsor of GBM AGILE and “take the baton” to the implementation phase of this innovative, groundbreaking platform trial.
GCAR’s broader mission is to lead the development and ongoing management of clinical trial platforms to accelerate the discovery and development of treatments for patients with rare and deadly diseases.
to Meaningful Progress
The GCAR Executive Leadership Team is comprised of experts in clinical research, drug development, clinical trials, technology development, commercialization, business development, and operations.
Together with our partners, we have an unwavering commitment to developing adaptive trials, sharing the research, nurturing relationships, and creating more access to treatments — ultimately driving faster, meaningful progress for patients.